secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001437749-23-003047
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 1.02, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Isoray terminates Chief R&D Officer William Cavanagh III, expects separation agreement
--------------------------------------------------------------------------------

- William Cavanagh III terminated as Chief R&D Officer effective Feb 7, 2023; termination triggers his Employment Agreement change-of-control provisions.
- Expected separation agreement: accrued wages at $341K annual salary, unreimbursed expenses (request within 5 days), plus one year health insurance premiums.
- Separation agreement will include a release of all claims by Cavanagh against the company; no assurance it will be finalized.
- Cavanagh remains subject to non-solicitation, non-disparagement, and confidentiality obligations post-termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000143774923003047/0001437749-23-003047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000143774923003047/isr20230210_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-003047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer